Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefuroxime axetil, quantity: 150 mg (equivalent: cefuroxime, qty 125 mg) - suspension, powder for - excipient ingredients: stearic acid; sucrose; povidone; flavour - zinnat suspension is indicated for the treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fondaparinux sodium, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee or hip replacement surgery.,arixtra is indicated for the prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.,arixtra is indicated for the treatment of acute deep venous thrombosis (dvt) and acute pulmonary embolism (pe).,arixtra is indicated for the treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) for whom urgent (<120 min) invasive management (pci) is not indicated.,arixtra is indicated for the treatment of st segment elevation myocardial infarction (stemi) in patients who are managed without any form of initial reperfusion therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - indometacin, quantity: 25 mg - capsule, hard - excipient ingredients: iron oxide yellow; magnesium stearate; lecithin; lactose monohydrate; gelatin; titanium dioxide; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - indocid is indicated in active stage of: rheumatoid arthritis, osteoarthritis, degenerative joint disease of the hip, ankylosing spondylitis, gout. it is also indicated for: acute musculoskeletal disorders, such as bursitis, tendonitis, synovitis, tenosynovitis, tenosynovitis, capsulitis of the shoulder, sprains and strains; low back pain (commonly referred to as lumbago); inflammation, pain and oedema following orthopaedic surgical procedures and nonsurgical procedures associated with reduction and immobilisation of fractures or dislocations; pain and associated symptoms of primary dysmenorrhoea.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium chloride, quantity: 595 mg; potassium bicarbonate, quantity: 384 mg; potassium carbonate, quantity: 152 mg - tablet, effervescent - excipient ingredients: leucine; macrogol 6000; acesulfame potassium; citric acid; sorbitol; aspartame; flavour - for the treatment and specific prevention of hypokalaemia.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose; titanium dioxide; hypromellose; triacetin - indications as at 10 february 2005: treatment of chronic granulocytic leukaemia. it has been shown to be superior to splenic irradiation when judged by survival times, control of spleen size and maintenance of haemoglobin levels. although not curative, busulfan reduces the total granulocyte mass, relieves disease symptoms and improves the clinical state of the patient. busulfan is not useful once blast transformation has occurred. busulfan produces prolonged remission in polycythaemia vera. it is especially useful in cases resistant to radiophosphorus (32 p) and where there is marked thrombocytosis. busulfan is useful in selected cases of essential thrombocythaemia and myelofibrosis.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg/ml (equivalent: prednisolone, qty 5 mg/ml) - oral liquid, solution - excipient ingredients: propylene glycol; dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate; disodium edetate; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water - whenever corticosteroid therapy is indicated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 11400 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - nadroparin calcium, quantity: 15200 anti-xa iu - injection, solution - excipient ingredients: calcium hydroxide; water for injections - treatment of deep vein thrombosis.